Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928421 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
A Phase 2 study of Varicose Veins, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00928421: Completed Phase 2 study of Varicose Veins, sponsored by Boston Scientific Corporation.
NCT00928421 is a Phase 2 study of Varicose Veins that has completed, run by Boston Scientific Corporation. The registered enrollment target is 16 participants, below the 168-participant average among 6 other Varicose Veins trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928421, a Phase 2 study of Varicose Veins, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effect and safety of Varisolve® 0.125% \[0.2%\]
Primary Outcome
Responders; elimination of reflux through the saphenofemoral junction and/or coplete occlusion of the great saphenous vein at 8 weeks, as measured by duplex ultrasound.
Conditions Studied
Interventions
- DRUG Polidocanol Endovenous Microfoam 0.125%
Study Locations (1)
Washington
- - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00928421 record still lists
NCT00928421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 168-participant average among 6 other Varicose Veins trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Varicose Veins appearing as the primary indexed condition, and to 1 intervention - of which Polidocanol Endovenous Microfoam 0.125% is the first listed.
NCT00928421 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00928421 about?
NCT00928421 is a clinical study titled "An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins". To determine the effect and safety of Varisolve® 0.125% \[0.2%\]
What is the current status of trial NCT00928421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-06. Estimated completion is 2010-01.
What conditions does trial NCT00928421 study?
This clinical trial studies the following conditions: Varicose Veins.
What interventions are being tested in trial NCT00928421?
The interventions under investigation include: Polidocanol Endovenous Microfoam 0.125% (DRUG).
Who is sponsoring clinical trial NCT00928421?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00928421 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Varicose Veins
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
COMPLETED · Phase 2
-
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
COMPLETED · Phase 3
-
COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
COMPLETED · Phase 4
-
Retrospective Review of Saphenous Vein Incompetence: Venaseal Versus Endovenous Thermal Ablation
COMPLETED
-
Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)
COMPLETED · Phase 1
-
Prevalence of MTHFR Polymorphisms in Venous Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia